Skip to main content
. 2021 Oct 18;12:704330. doi: 10.3389/fpsyt.2021.704330

Table 1.

Demographic and clinical characteristics of the total sample.

Variables Total sample (N = 41)
Mean (SD)
Age 48.5 (14.3)
BMI 27.5 (5.6)
Episode duration (weeks) 26.9 (29.0)
Number of depressive episodes 6.1 (8.1)
Baseline results (before infusion)
SHAPS 9.6 (3.5)
IDS-30 total 46.7 (13.1)
IDS item no. 18 1.2 (1.2)
Diagnosis N (%)
MDD 28 (68.3%)
BD 13 (31.7%)
Sex
    Females 26 (63.4%)
    Males 15 (36.6%)
Education
    Primary 2 (4.9%)
    Secondary 4 (9.8%)
    Vocational 16 (39.0%)
    Higher 19 (46.3%)
Employment status
    Unemployed 8 (19.5%)
    Pension 16 (39.0%)
    Retirement 7 (17.1%)
    Employed 9 (22.0%)
    Study 1 (2.4%)
Marital status
    Single 11 (26.8%)
    Informal relationship 2 (4.9%)
    Married 20 (48.8%)
    Divorced 5 (12.2%)
    Widowed 3 (7.3%)
Concomitant meds
    TCA MDD: 4 (14.3%), BD: 0 (0%)
    SSRI MDD: 16 (57.1%), BD: 4 (30.8%)
    SNRI MDD: 5 (17.9%), BD: 5 (38.5%)
    Other MDD: 11 (39.3%), BD: 3 (23.1%)
    Antipsychotics MDD: 8 (28.6%), BD: 8 (61.5%)
    Mood stabilizers MDD: 10 (35.7%), BD: 10 (76.9%)
    Lithium MDD: 0 (0%), BD: 3 (23.1%)
    BDZ MDD: 12 (42.9%), BD: 8 (61.5%)

SHAPS, Snaith–Hamilton Pleasure Scale; IDS-SR 30, 30-Item Inventory for Depressive Symptomatology—Self Report; SD, standard deviation; BMI, body mass index; MDD, major depressive disorder; BD, Bipolar disorder; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin and noradrenaline reuptake inhibitors; AD, antidepressants; TCA, tricyclic antidepressants; BDZ, benzodiazepines.